Table of Content

1. Market Overview

1.1 Introduction
1.2 Classification
1.3 Causes & Symptoms
1.4 Diagnosis
1.5 Treatment


2. Global Spinal Muscular Atrophy Market

2.1 Global Spinal Muscular Atrophy Market Value Forecast
2.2 Global AVXS-101 Gene Therapy Value Forecast
2.3 Global AVXS-101 Gene Therapy Value Forecast by Region
2.4 Global SRK-015 Drug Value Forecast
2.5 Global SRK-015 Drug Value Forecast by Region
2.6 Global Spinal Muscular Atrophy Incidence by Region
2.7 Global Spinal Muscular Atrophy Prevalence by Region


3. Regional Spinal Muscular Atrophy Market

3.1 The U.S. AVXS-101 Gene Therapy Value Forecast
3.2 The U.S. AVXS-101 Gene Therapy Value Forecast by Disease Type
3.2.1 The U.S. AVXS-101 Gene Therapy Value Forecast by Type I
3.2.2 The U.S. AVXS-101 Gene Therapy Value Forecast by Type II
3.3 The U.S. SRK-015 Drug Value Forecast
3.4 The U.S. SRK-015 Drug Value Forecast by Disease Type
3.4.1 The U.S. SRK-015 Drug Value Forecast by Type I
3.4.2 The U.S. SRK-015 Drug Value Forecast by Type III
3.5 EU AVXS-101 Gene Therapy Value Forecast
3.6 EU AVXS-101 Gene Therapy Value Forecast by Disease Type
3.6.1 EU AVXS-101 Gene Therapy Value Forecast by Type I
3.6.2 EU AVXS-101 Gene Therapy Value Forecast by Type III
3.7 EU SRK-015 Drug Value Forecast
3.8 EU SRK-015 Drug Value Forecast by Disease Type
3.8.1 EU SRK-015 Drug Value Forecast by Type I
3.8.2 EU SRK-015 Drug Value Forecast by Type III


4. Market Dynamics

4.1 Growth Drivers
4.1.1 Rising Pharmaceuticals Research and Development (R&D) Expenditures
4.1.2 Increasing Personal Healthcare Expenditure
4.1.3 Accelerating Economic Growth
4.1.4 Growing Spinal Muscular Atrophy Occurrence

4.2 Key Trends and Developments
4.2.1 Progressing Drug Pipeline
4.2.2 High Preference for Gene Therapy

4.3 Challenges
4.3.1 Lethargic Drug Approval Process
4.3.2 Associated Business Risk


5. Competitive Landscape

5.1 Global Spinal Muscular Atrophy Market
5.1.1 Key Players - Revenue Comparison
5.1.2 Key Players – Drug Features Comparison
5.1.3 Key Players – Market Cap Comparison


6. Company Profiles

6.1 Biogen Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies

6.2 Novartis International AG
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies

6.3 Roche Holding AG
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies

6.4 Cytokinetics, Inc
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies



List of Figures



Global Spinal Muscular Atrophy Market Value Forecast (2018-2023)
Global AVXS-101 Gene Therapy Market Forecast (2019-2023)
Global AVXS-101 Gene Therapy Value Forecast by Region (2019-2023)
Global SRK-015 Drug Value Forecast (2022-2026)
Global SRK-015 Drug Value Forecast by Region (2022-2026)
Global Spinal Muscular Atrophy Incidence by Region (2018)
Global Spinal Muscular Atrophy Prevalence by Region (2018)
The U.S. AVXS-101 Gene Therapy Value Forecast (2019-2023)
The U.S. AVXS-101 Gene Therapy Value Forecast by Disease Type (2019-2023)
The U.S. AVXS-101 Gene Therapy Value Forecast by Type I (2019-2023)
The U.S. AVXS-101 Gene Therapy Value Forecast by Type II (2020-2024)
The U.S. SRK-015 Drug Value Forecast (2022-2026)
The U.S. SRK-015 Drug Value Forecast by Disease Type (2022-2026)
The U.S. SRK-015 Drug Value Forecast by Type I (2022-2026)
The U.S. SRK-015 Drug Value Forecast by Type III (2022-2026)
EU AVXS-101 Gene Therapy Value Forecast (2020-2024)
EU AVXS-101 Gene Therapy Value Forecast by Disease Type (2020-2024)
EU AVXS-101 Gene Therapy Value Forecast by Type I (2020-2024)
EU AVXS-101 Gene Therapy Value Forecast by Type III (2021-2025)
EU SRK-015 Drug Value Forecast (2023-2027)
EU SRK-015 Drug Value Forecast by Disease Type (2023-2027)
EU SRK-015 Drug Value Forecast by Type I (2023-2027)
EU SRK-015 Drug Value Forecast by Type III (2023-2027)
Global Pharmaceuticals Research and Development (R&D) Expenditures (2014-2018)
Global HealthCare Expenditure Per Capita (2014-2018)
Global Gross Domestic Product (GDP) per Capita (2014-2018)
Spinal Muscular Atrophy Drugs Approval Procedure
Key Players – Market Cap Comparison (2019)
Biogen Revenues by Business Segments (2018)
Biogen Revenues and Net Income (2014-2018)
Biogen R&D Expenditures (2015-2017)
Novartis Net Sales by Business Segments (2018)
Novartis Net Sales and Net Income (2014-2018)
Roche Sales by Business Segments (2018)
Roche Sales and Net Income (2014-2018)
Cytokinetics Revenues and Net Income (Loss) (2013-2017)
Cytokinetics R&D Expenditures (2015-2017)

List of Tables



Spinal Muscular Atrophy Drugs under Development (2018)
Key Players - Revenue Comparison (2018)
Key Players - Drug Features Comparison (2018)
Cytokinetics Product Pipeline (2019)
Cytokinetics Partnership Renewal Agreements (2018)